The International Society for Pediatric and Adolescent Diabetes Clinical Practice Consensus Guideline 2018 for management of diabetic ketoacidosis (DKA) and the hyperglycemic hyperosmolar state provide comprehensive guidance for management of DKA in young people Intravenous (IV) infusion of insulin remains the treatment of choice for treating DKA;however, the policy of many hospitals around the world requires admission to an intensive care unit (ICU) for IV insulin infusion During the coronavirus 2019 (COVID‐19) pandemic or other settings where intensive care resources are limited, ICU services may need to be prioritized or may not be appropriate due to risk of transmission of infection to young people with type 1 or type 2 diabetes The aim of this guideline, which should be used in conjunction with the ISPAD 2018 guidelines, is to ensure that young individuals with DKA receive management according to best evidence in the context of limited ICU resources Specifically, this guideline summarizes evidence for the role of subcutaneous insulin in treatment of uncomplicated mild to moderate DKA in young people and may be implemented if administration of IV insulin is not an option
ISPAD Clinical Practice Consensus Guideline: Diabetic ketoacidosis in the time of COVID‐19 and resource‐limited settings‐role of subcutaneous insulin